

Complications of Age-related Macular Degeneration Prevention Trial FV12 TREATMENT FORM - Section I: Evaluation for FV12 Treatment

CAPT TE FORM (302.2) 09/10/01, Page 1 of 3


I. Evaluation for FV12 Treatment

NOTE: This section of the FV12 Treatment Form must be completed for <u>all</u> patients in the CAPT Study.

1	Which ev	e was	randomized	tο	CAPT	treatment?
1.	VVIIICII CY	c was	Tariaorriizca	LU	ו ותט	ti CatillClit:

$$\binom{1}{0}$$
 $\binom{1}{0}$ Right Left

2. Will this eye be treated at FV12 in accordance with the CAPT protocol?



3. Print name and certification number of ophthalmologist performing evaluation for re-treatment:

	/
Name	

4. Date of FV12 treatment evaluation:

	-	-
Month	Day	Year

2A. If YES, complete questions 3 and 4 **and** Section II of this form.

2B. If, NO, check best reason:
Less than the equivalent of 10

large drusen in this eye $()_1$

Presence of CNV or serous PED in either eye ()₂

Reading Center recommends no further protocol treatment

Patient unwilling to be retreated ()₄

New Geographic Atrophy <500 microns to foveal center or \geq 1

MPS Disc Areas ()₅

Other, specify: $()_6$

a. _____

Complete questions 3 and 4. Since patient will not be treated, do not complete Section II of this form.

Coord Ctr Use Only: Initials
Date:

/isit: 12	ID. No.: C
orm: TE	Name Code:



Complications of Age-related Macular Degeneration Prevention Trial FV12 TREATMENT FORM - Section II: FV12 Treatment

CAPT TE FORM **(303.2)** 09/10/01, Page 2 of 3

II. FV12 Treatment

NOTE: This section must be completed for patients treated at FV12 according to CAPT protocol.

			FV12 Treatment Pattern
1.	Eye treated? $(\)_0 \ (\)_1$ Right Left		2,000μm
2.	Date treatment was performed:		Fovea 1,000μm
	Month Day Year		
3.	Specify contact lens used and indicate spot size setting on laser: (check one)		= Drusen
	Goldmann, Mainster Standard or Volk Area Centralis with a 100μ setting on laser () ₁		
	Panfunduscopic, Volk TransEquator or Mainster Wide Field with a 75μ setting on laser () $_2$		
	Volk QuadrAspheric, Mainster Ultra Field PRP or Volk SuperQuad 160 with a 50μ setting on laser () $_3$		
	Volk SuperMacula 2.0 with a 200μ setting on laser ($\)_{_{4}}$		
	Other lens and/or spot size setting (specify) () $_5$		Specify lens and spot size setting on
4.	Which wavelength laser was used? a. Argon green b. Other wavelength () ₁		laser:
5.	Indicate each duration of exposure used: a. 0.1 second () 1 b. Other () 1		Describe:
all	<u>TE</u> : For the following two questions, include burns applied regardless of whether a visible on was created.	5A.	Describe:
6.	Number of test burns applied outside the area designated for protocol treatment:		
		Visit: 12 Form: TE	ID. No.: C Name Code:



Month Day Year

Complications of Age-related Macular Degeneration Prevention Trial FV12 TREATMENT FORM - Section II: FV12 Treatment

CAPT TE FORM **(303.2)** 09/10/01, Page 3 of 3

7.	Total number of burns applied within the area designated for protocol treatment:	
8.	Any laser treatment complications? () ₁ () ₀ Yes No	→
9.	Print name and certification number of ophthalmologist performing treatment: Name Cert#	8A. Specify complication: a. Hemorrhage () ₁ b. Other, specify: () ₁ c.
10.	Date the treatment stereo color photographs were taken:	
	Month Day Year	Treatment photographs (stereo color photographs and stereo red-free color photographs of the macula) should be taken promptly following treatment, but
11.	Print name and certification number of photographer taking the treatment stereo color photographs: /	no later than 2 days following treatment.
12.	Print name and certification number of clinic coordinator checking form for completeness:	
	/	
13.	Date checked for completeness:	

 Visit: 12
 ID. No.: ___ - _ _ - C

 Form: TE
 Name Code: __ _ _ _ _